Invivyd (NASDAQ:IVVD) Posts Earnings Results, Beats Estimates By $0.10 EPS

Invivyd (NASDAQ:IVVD) announced its quarterly earnings data on Thursday. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.10, Zacks reports. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $13.57 million.

Invivyd Stock Up 2.6 %

NASDAQ IVVD opened at $0.74 on Friday. The stock has a market cap of $88.35 million, a P/E ratio of -0.38 and a beta of 0.09. The company’s 50-day simple moving average is $0.97 and its 200 day simple moving average is $0.87. Invivyd has a twelve month low of $0.35 and a twelve month high of $4.74.

Analyst Upgrades and Downgrades

IVVD has been the subject of a number of research analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Invivyd in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research report on Monday, February 24th. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $7.89.

Insider Activity at Invivyd

In related news, Director Terrance Mcguire sold 86,545 shares of the company’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $0.48, for a total value of $41,541.60. Following the sale, the director now owns 3,170,231 shares of the company’s stock, valued at $1,521,710.88. The trade was a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 246,138 shares of company stock valued at $120,902 over the last quarter. 17.90% of the stock is owned by company insiders.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.